Survival rates of adult patients with H odgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
Cancer Reports · 2023
DOI: 10.1002/cnr2.1839 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Reports, 2023. Verfasst von Tawatchai Suwanban und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The survival rate of adult patients with Hodgkin lymphoma (HL) depends on the responses to standard chemotherapy, radiotherapy, or combined therapy. Resource‐limited countries face numerous obstacles in supporting patients with HL who undergo chemotherapy, especially in advanced stages.
Aim
To analyze the survival outcomes of adult patients with HL after combined‐modality treatment (CMT) with involved‐field or non‐involved‐field radiotherapy. Methods and Results We retrospectively reviewed the medical records of 90 adult patients with HL who received CMT at Rajavithi Hospital, Bangkok between 2007 and 2021. Patients with stage I‐IV disease received different therapies depending on their risk group. The risk groups were evaluated according to initial response, bulky disease, and B symptoms. Patients (n = 90) who underwent CMT were followed up for 34.7 months (range, 1–141 months). The median follow‐up periods of early and advanced‐stage patients were 53.1 months and 23.5 months, respectively. The estimated 5‐year overall survival (OS) and progression‐free survival (PFS) rates of patients with advanced‐stage diseases were 85% and 62%, respectively. There was a difference in the 3‐year overall survival among advance‐stage patients who underwent ABVD (94%) compared to those administered BEACOPPesc (50%), and the 3‐year PFS (84%) among patients who underwent ABVD was higher than that among those administered BEACOPPesc (66%). Radiotherapy increased toxicity but did not improve the survival rate.
Conclusion
Chemotherapy administered to patients with advanced‐stage adult HL was more effective than BEACOPPesc when ABVD was administered. Our findings are relevant for hospitals with limited resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.
- Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Tawatchai Suwanban, Supat Chamnanchanunt, Pravinwan Thungthong, Chajchawan Nakhahes, Udomsak Bunworasate
Zitieren
APA
Suwanban, T., Chamnanchanunt, S., Thungthong, P., Nakhahes, C., Iam-Arunthai, K., Akrawikrai, T., & Bunworasate, U. (2023). Survival rates of adult patients with H odgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study. Cancer Reports. https://doi.org/10.1002/cnr2.1839
Vancouver
Suwanban T, Chamnanchanunt S, Thungthong P, Nakhahes C, Iam-Arunthai K, Akrawikrai T, et al. Survival rates of adult patients with H odgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study. Cancer Reports. 2023. doi:10.1002/cnr2.1839
BibTeX
@article{Suwanban2023,
author = {Suwanban, Tawatchai and Chamnanchanunt, Supat and Thungthong, Pravinwan and Nakhahes, Chajchawan and Iam-Arunthai, Kunapa and Akrawikrai, Tananchai and Bunworasate, Udomsak},
title = {Survival rates of adult patients with H odgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study},
journal = {Cancer Reports},
year = {2023},
doi = {10.1002/cnr2.1839}
}
EUVIMED